Aktienanalyse zu Intuitive Surgical Inc (ISRG)ISRGIntuitive Surgical Inc

Intuitive Surgical, Inc. develops, manufactures, and markets da Vinci surgical systems and the Ion endoluminal system. The Company specializes in invasive care and robotic-assisted surgery. Its technologies include the da Vinci surgical systems and the Ion endoluminal system. The da Vinci surgical system is designed to enable surgeons to perform a range of surgical procedures within its targeted general surgery, urologic, gynecologic, cardiothoracic, and head and neck specialties and consists of a surgeon's console or consoles, a patient-side cart, and a high-performance vision system. The Ion endoluminal system is a flexible, robotic-assisted, catheter-based platform for which the cleared indication is minimally invasive biopsies in the lung and consists of a system cart, a controller, a catheter, and a vision probe. Its Ion system extends its commercial offering beyond surgery into diagnostic and endoluminal procedures. It operates in the Healthcare sector (ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUP industry).

Intuitive Surgical Inc (ISRG) is currently at a price of $372.60, which is significantly lower than the analyst price target of $500 set by Oppenheimer. However, the stock has a low RSI of 41.97, indicating it is nearing oversold territory. The company faces strong competition, which is a risk, as evidenced by the recent downgrade from HSBC, which set a lower target of $391. Given the mixed signals from analysts and the current market pressures, it is advisable to hold rather than buy at this time.

17 analysts cover ISRG: 11 rate it Buy, 5 Hold and 1 Sell. The average price target is 637.32.